Cytokinetics (CYTK) Corporate presentation summary

Mission and vision

• Aims to develop innovative medicines for cardiovascular and neuromuscular diseases with impaired muscle function.

• Vision 2030 targets leadership in muscle-focused biopharma, reaching over 100,000 patients globally and advancing 10 NMEs across 3 indications.

• Focus on equitable, patient-centric culture and global access to therapies.

Product portfolio and pipeline

• MYQORZO (aficamten) approved for symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in the US, China, EU, and UK.

• Pipeline includes aficamten for pediatric oHCM and non-obstructive HCM (nHCM), omecamtiv mecarbil for HFrEF, and ulacamten for HFpEF.

• Multiple late-stage trials ongoing, including MAPLE-HCM, CEDAR-HCM, ACACIA-HCM, and COMET-HF.

Commercial and market strategy

• Strong US and European launches for MYQORZO, with expansion into Germany and the UK, and regulatory reviews in Canada, Switzerland, Hong Kong, and Taiwan.

• Specialty cardiology franchise targets high-ROI prescribers and leverages a highly experienced sales team.

• Patient and HCP awareness campaigns have driven >30% patient awareness and rapid NBRx growth.

• Market access strategy has achieved nearly 90% Medicare parity and >50% commercial coverage, aiming for parity by Q4 2026.